ArticleCell communication and signaling : CCS2026
Genetically engineered macrophages delivering TRAIL targeting the Wnt/β-catenin pathway to induce cytotoxicity against TNBC.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Ferroptosis-related gene EPAS1 suppresses breast cancer progression by inhibiting M2 macrophage polarization.Discover oncology · 2026Article
- CAR-T cell therapy in cancer immunotherapy - Biology, clinical successes, and emerging challenges: A review.Biomolecules & biomedicine · 2026Review
- Research Progress on Signaling Pathways in Breast Cancer Bone Metastasis.Oncology research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Triple-negative breast cancer (TNBC) is a highly aggressive cancer subtype that lacks effective targeted therapies, posing significant challenges in its treatment. Engineered macrophages have emerged as promising tools for drug delivery and immunotherapy in cancer treatment. In this study, we developed a drug delivery strategy based on genetically modified macrophages. These macrophages were engineered in two ways to continuously secrete the apoptosis signal activator TRAIL, including monomeric TRAIL (Mono-TRAIL) and trimeric TRAIL (Tri-TRAIL). Engineered macrophages, particularly Tri-TRAIL-M, were found to promote M1 macrophage polarization within the tumor microenvironment (TME), thereby enhancing antitumor immune responses. Simultaneously, the engineered macrophages significantly inhibited the Wnt/β-catenin signaling pathway in TNBC cells and induced G2/M phase cell cycle arrest. In an in vivo TNBC model, Tri-TRAIL-M effectively suppressed tumor growth, highlighting its therapeutic potential. These findings suggest that TRAIL-secreting engineered macrophages, especially Tri-TRAIL-M, provide a promising strategy for TNBC cytotoxicity. This approach opens new avenues for macrophage-based therapies in TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.